The COVID-19 pandemic is halting and slowing down clinical trials, and the Food and Drug Administration is offering guidelines to adjust to these new challenges. Clinical trials may slow, stop or ...
If followed, clinical trial protocols established during the COVID-19 pandemic could allow more patients participate. The COVID-19 pandemic caused a major shift in the way that health care was ...
When discussing the future of clinical trials, people often focus on the promise of exciting new technologies, including artificial intelligence (AI) and predictive modeling. However, even the most ...
Drug and Device Companies Should Plan for Rapid Changes to Interactions with IRBs/IECs, Clinical Trial Sites, and Human Study Subjects The Food and Drug Administration (“FDA”) as well as the European ...
This study used surveys and live interviews. Forty-one major industry and National Cancer Institute Network groups (sponsors) overseeing anticancer treatment trials open in the United States from ...
Method of treatment patents based on Phase II and Phase III clinical trial protocols are routinely pursued to extend patent exclusivity and strategically build a patent portfolio for a drug asset. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results